Published in Eur J Biochem on February 01, 1993
Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest (1995) 3.14
DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet (1998) 1.94
Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Circ Res (2007) 1.81
Determination of paraoxonase 1 status without the use of toxic organophosphate substrates. Circ Cardiovasc Genet (2008) 1.76
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest (1997) 1.71
Proteomic diversity of high density lipoproteins: our emerging understanding of its importance in lipid transport and beyond. J Lipid Res (2013) 1.57
Mildly oxidized LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest (1997) 1.45
Paraoxonase gene mutations in amyotrophic lateral sclerosis. Ann Neurol (2010) 1.20
Reconsideration of the catalytic center and mechanism of mammalian paraoxonase/arylesterase. Proc Natl Acad Sci U S A (1995) 1.17
Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J (1994) 1.15
Overexpression of apolipoprotein AII in transgenic mice converts high density lipoproteins to proinflammatory particles. J Clin Invest (1997) 1.14
Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE) study. Am J Hum Genet (2002) 1.10
Human PON1, a biomarker of risk of disease and exposure. Chem Biol Interact (2010) 1.09
HDL is the major lipoprotein carrier of plasma F2-isoprostanes. J Lipid Res (2008) 1.09
Genetic-dietary regulation of serum paraoxonase expression and its role in atherogenesis in a mouse model. J Clin Invest (1996) 1.08
The roles of PON1 and PON2 in cardiovascular disease and innate immunity. Curr Opin Lipidol (2009) 1.00
Phospholipid transfer protein in human plasma associates with proteins linked to immunity and inflammation. Biochemistry (2010) 0.96
Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting cad risk in North-West Indian Punjabis. PLoS One (2011) 0.95
Hydrolysis of platelet-activating factor by human serum paraoxonase. Biochem J (2001) 0.94
Clusterin: modulation of complement function. Clin Exp Immunol (1994) 0.91
Genetics of platelet inhibitor treatment. Br J Clin Pharmacol (2014) 0.89
The genetics of vascular complications in diabetes mellitus. Cardiol Clin (2010) 0.85
Temporal and tissue-specific patterns of Pon3 expression in mouse: in situ hybridization analysis. Adv Exp Med Biol (2010) 0.83
Implications of serum paraoxonase activity in obesity, diabetes mellitus, and dyslipidemia. Indian J Endocrinol Metab (2013) 0.82
Paraoxonase 1 activities and polymorphisms in autism spectrum disorders. J Cell Mol Med (2009) 0.79
Plasma Clusterin and Lipid Profile: A Link with Aging and Cardiovascular Diseases in a Population with a Consistent Number of Centenarians. PLoS One (2015) 0.79
Isolation and complete covalent structure of liver microsomal paraoxonase. Biochem J (1999) 0.77
Serum paraoxonase activity, total thiols levels, and oxidative status in patients with acute brucellosis. Wien Klin Wochenschr (2015) 0.77
Effects of water extracts of Graptopetalum paraguayense on blood pressure, fasting glucose, and lipid profiles of subjects with metabolic syndrome. Biomed Res Int (2013) 0.76
Serum paraoxonase activity and lipid hydroperoxide levels in adult football players after three days football tournament. Afr Health Sci (2013) 0.76
Valproic acid inhibits glioblastoma multiforme cell growth via paraoxonase 2 expression. Oncotarget (2017) 0.75
Effects of paraoxonase activity and gene polymorphism on coronary vasomotion. EJNMMI Res (2011) 0.75
Antioxidative Activity after Rosuvastatin Treatment in Patients with Stable Ischemic Heart Disease and Decreased High Density Lipoprotein Cholesterol. Korean Circ J (2016) 0.75
Profile of the Paraoxonase 1 (PON1) Gene 192Q/R Polymorphism and Clinical Associations among Older Singaporean Chinese with Alzheimer's and Mixed Dementia. Dement Geriatr Cogn Dis Extra (2016) 0.75
Human paraoxonase 1 overexpression in mice stimulates HDL cholesterol efflux and reverse cholesterol transport. PLoS One (2017) 0.75
Relationship of PON1 192 and 55 gene polymorphisms to calcific valvular aortic stenosis. Am J Cardiovasc Dis (2012) 0.75
Swarming of Pseudomonas aeruginosa is dependent on cell-to-cell signaling and requires flagella and pili. J Bacteriol (2000) 4.59
Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet (1995) 2.29
The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol (1994) 2.04
Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest (1997) 1.71
Rhizobium meliloti 1021 has three differentially regulated loci involved in glutamine biosynthesis, none of which is essential for symbiotic nitrogen fixation. J Bacteriol (1989) 1.58
Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol (2000) 1.53
Energy expenditure and substrates oxidative patterns, after glucose, fat or mixed load in normal weight subjects. Eur J Clin Nutr (1997) 1.39
Toxicologic evaluation of FK 506. Transplant Proc (1990) 1.36
Actin isoform synthesis and mRNA levels in quiescent and proliferating rat aortic smooth muscle cells in vivo and in vitro. Lab Invest (1986) 1.33
Paraoxonase promoter polymorphism T(-107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med (Berl) (2001) 1.18
Mycobacterium haemophilum causing perihilar or cervical lymphadenitis in healthy children. J Pediatr (1992) 1.17
Characterization of subpopulations of lipoprotein particles isolated from human cerebrospinal fluid. Biochim Biophys Acta (1995) 1.16
Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J (1994) 1.15
Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis (1999) 1.12
Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. Arterioscler Thromb Vasc Biol (1997) 1.12
Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations. J Lipid Res (2001) 1.12
Apolipoprotein B metabolism in homozygous familial hypercholesterolemia. J Lipid Res (1989) 1.09
Persistent pupillary membrane in basenji dogs. Vet Rec (1991) 1.08
Serum paraoxonase is reduced in type 1 diabetic patients compared to non-diabetic, first degree relatives; influence on the ability of HDL to protect LDL from oxidation. Atherosclerosis (2001) 1.08
Mapping functional domains of the polycomb protein of Drosophila melanogaster. Chromosome Res (1995) 1.06
2-Amino-4-phosphonobutyric acid as a glutamate antagonist on locust muscle. Nature (1976) 1.06
Asymptomatic bacteriuria in diabetes mellitus. N Engl J Med (1967) 1.05
A monoclonal anti-idiotypic antibody against anti-receptor antibodies from myasthenic sera. Eur J Immunol (1982) 1.02
Low density lipoprotein causes general cellular activation with increased phosphatidylinositol turnover and lipoprotein catabolism. Proc Natl Acad Sci U S A (1988) 1.00
Factors affecting the in-vitro development to blastocysts of bovine oocytes matured and fertilized in vitro. J Reprod Fertil (1991) 1.00
Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects. Diabetes (1990) 0.96
Relationship between plasma insulin levels and high density lipoprotein cholesterol levels in healthy men. Diabetologia (1981) 0.95
Characterization of a human high density lipoprotein-associated protein, NA1/NA2. Identity with SP-40,40, an inhibitor of complement-mediated cytolysis. Arterioscler Thromb (1991) 0.94
Differential effects of low density lipoproteins on insulin-like growth factor-1 (IGF-1) and IGF-1 receptor expression in vascular smooth muscle cells. J Biol Chem (2000) 0.94
Sensory innervation of the rat portal vein and the hepatic artery. J Auton Nerv Syst (1984) 0.91
Protein heterogeneity of lipoprotein particles containing apolipoprotein A-I without apolipoprotein A-II and apolipoprotein A-I with apolipoprotein A-II isolated from human plasma. J Lipid Res (1988) 0.90
Association of elevated lipoprotein(a) levels and coronary heart disease in NIDDM patients. Relationship with apolipoprotein(a) phenotypes. Diabetologia (1994) 0.89
Monoclonal antibodies directed against the neurotransmitter binding site of nicotinic acetylcholine receptor. FEBS Lett (1980) 0.89
Induction of multiple germ tubes in Neurospora crassa by antitubulin agents. Eur J Cell Biol (1988) 0.88
Heterogeneity in the properties of the trypanolytic factor in normal human serum. Mol Biochem Parasitol (1994) 0.87
Treatment of hyperlipoproteinemia (HLP) type II A with a new phenoxy-isobuturic acid derivative, procetofen. Int J Clin Pharmacol Biopharm (1979) 0.85
[Dyslipidemia in the diabetic patient. Recommendations of ALFEDIAM (French Language Association for the Study of Diabetes and Metabolic Diseases)]. Diabete Metab (1995) 0.85
Adrenergic and peptidergic (substance P and vasoactive intestinal polypeptide) innervation of the rat portal vein. Blood Vessels (1982) 0.85
Iron-ascorbic acid-induced oxidant stress and its quenching by paraoxonase 1 in HDL and the liver: comparison between humans and rats. J Cell Biochem (2005) 0.84
Aspirin use is associated with higher serum concentrations of the anti-oxidant enzyme, paraoxonase-1. Diabetologia (2003) 0.83
Acute hyperinsulinemia and very-low-density and low-density lipoprotein subfractions in obese subjects. Am J Clin Nutr (2000) 0.83
Lipoprotein (a) and vascular disease in diabetic patients. Diabetologia (1995) 0.83
Substance P-containing nerve fibres in large peripheral blood vessels of the rat. Cell Tissue Res (1983) 0.82
Immunoaffinity fractionation of high-density lipoprotein subclasses 2 and 3 using anti-apolipoprotein A-I and A-II immunosorbent gels. Biochim Biophys Acta (1989) 0.82
Iron excess, early glucose intolerance and impaired insulin secretion in idiopathic haemochromatosis. Eur J Clin Invest (1973) 0.81
Beneficial effect of hormone replacement therapy on weight loss in obese menopausal women. Maturitas (1999) 0.81
HDL particle associated proteins in plasma and cerebrospinal fluid: identification and partial sequencing. Appl Theor Electrophor (1988) 0.81
Associations between HDL oxidation and paraoxonase-1 and paraoxonase-1 gene polymorphisms in families affected by familial combined hyperlipidemia. Nutr Metab Cardiovasc Dis (2004) 0.81
Distribution of apolipoprotein E between free and A-II complexed forms in very-low- and high-density lipoproteins: functional implications. Biochim Biophys Acta (1991) 0.81
Liver glycerokinase deficiency in man with hyperglycerolaemia and hypertriglyceridaemia. Eur J Clin Invest (1984) 0.81
European Lipoprotein Club: report of the 20th annual conference, Tutzing, 8-11 September 1997. Atherosclerosis (1998) 0.81
HDL lipids in close relatives of coronary heart disease patients. Environmental and genetic influences. Atherosclerosis (1979) 0.81
Modulation by blood glucose levels of activity and concentration of paraoxonase in young patients with type 1 diabetes mellitus. Metabolism (2001) 0.81
Spinal substance P transmits bradykinin but not osmotic stimuli from hepatic portal vein to hypothalamus in rat. Neuroscience (1984) 0.80
Immunofractionation of high density lipoprotein subclasses 2 and 3. Similarities and differences of fractions isolated from male and female populations. Atherosclerosis (1990) 0.80
Isolation of a glutaminergic receptor fraction from locust muscle. Biochem Soc Trans (1977) 0.80
Metabolic effects of dietary fiber from dehulled soybeans in humans. Am J Clin Nutr (1983) 0.80
Angiotensin II promotes selective uptake of high density lipoprotein cholesterol esters in bovine adrenal glomerulosa and human adrenocortical carcinoma cells through induction of scavenger receptor class B type I. Endocrinology (2001) 0.80
Apolipoprotein E polymorphisms and mortality in Italian type 2 diabetic patients. Eur J Clin Invest (2003) 0.79
The paraoxonase PON1 promoter polymorphism C(-107)T is associated with increased serum glucose concentrations in non-diabetic patients. Diabetologia (2001) 0.79
[Apoprotein E (apo E) phenotype and serum lipids in diabetics]. Schweiz Med Wochenschr (1987) 0.79
The apolipoprotein epsilon2 allele and the severity of coronary artery disease in Type 2 diabetic patients. Diabet Med (2001) 0.79
Phenotyping is an accurate means of analysing the principal apolipoprotein E isoforms. Clin Chim Acta (1994) 0.78
Effects of short-term modest weight loss on fasting and post-prandial lipoprotein sub-fractions in type 2 diabetes mellitus patients. Diabetes Metab (2001) 0.78
High density lipoprotein cholesterol in male relatives of patients with coronary heart disease. Atherosclerosis (1979) 0.78
The distribution profiles of very low density and low density lipoproteins in poorly-controlled male, type 2 (non-insulin-dependent) diabetic patients. Diabetologia (1991) 0.78
Apolipoprotein E polymorphism as a risk factor for vascular disease in diabetic patients. Diabetes Care (1995) 0.78
Neural actions of several substance P antagonists in the rat spinal cord. Neurosci Lett (1983) 0.78
Postprandial lipemia differentially influences high density lipoprotein subpopulations LpAI and LpAI,AII. J Lipid Res (1994) 0.78
HDL and coronary heart disease: a familial trend. Adv Exp Med Biol (1987) 0.77
Effects of morphine sulphate on pituitary-testicular morphology of rats. Toxicol Lett (1980) 0.77
Toxicological studies on 1-substituted-indazole-3-carboxylic acids. Chemotherapy (1981) 0.77
Characterization of iodinated derivatives of alpha-bungarotoxin. Hoppe Seylers Z Physiol Chem (1980) 0.77
Acquired (secondary) forms of hypertriglyceridemia. Am J Cardiol (1991) 0.77
Underexpression of the apolipoprotein E4 isoform in an Italian population. Arterioscler Thromb (1993) 0.77
Apoprotein D in a healthy, male population and in male myocardial infarction patients and their male, first-degree relatives. Atherosclerosis (1986) 0.77
Factors influencing the low density lipoprotein profile in type 2 diabetic patients. Diabet Med (1995) 0.77
Proteolytic cleavage of a spectrin-related protein by calcium-dependent protease in Neurospora crassa. Curr Microbiol (2006) 0.77
Decreased HDL cholesterol in prepubertal and pubertal children of CHD patients. Atherosclerosis (1980) 0.76
HDL cholesterol levels in patients with myocardial infarction and their families. Atherosclerosis (1986) 0.76
High-resolution two-dimensional protein electrophoresis of pathological plasma/serum. Appl Theor Electrophor (1991) 0.76
Injury-induced synthesis and release of apolipoprotein E and clusterin from rat neural cells. Eur J Neurosci (1996) 0.76
Lipoprotein(a) and retinopathy in IDDM and NIDDM patients. Diabetes Care (1997) 0.76
Myeloperoxidase and paraoxonase-1 in type 2 diabetic patients. Nutr Metab Cardiovasc Dis (2009) 0.76
Canine pituitary-testicular function in relation to toxicity testing. Toxicology (1979) 0.76
Gender differences in a type 2 (non-insulin-dependent) diabetic population with respect to apolipoprotein E phenotype frequencies. Diabetologia (1993) 0.76
Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level. Am J Ophthalmol (1994) 0.75
Immunohistochemical evidence for mast cells containing 5-hydroxytryptamine in rat portal vein. Agents Actions (1986) 0.75
Marked changes of lipid levels during puberty in a patient with lipoprotein lipase deficiency. Eur J Pediatr (1997) 0.75
The (Ala-Val) mutation of methylenetetrahydrofolate reductase as a genetic risk factor for vascular disease in non-insulin-dependent diabetic patients. Am J Hum Genet (1997) 0.75